GlassScriptPhysician profile
David W Dorton
NPI 1073502209
$7,606.13
in general payments reported to CMS, 2019-2025
34 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $361 · 2021: $772 · 2022: $1,005 · 2023: $2,029 · 2024: $1,842 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,866 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,865.91 |
| Education | $106.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,078.26 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $760.45 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Organogenesis INC. | $612.28 | 2021-2024 | Puraply, Matrix, Affinity |
| Lilly USA, LLC | $479.87 | 2019-2024 | Olumiant, Taltz |
| Leo Pharma INC. | $458.74 | 2019-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $377.57 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $365.62 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $364.12 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $359.23 | 2020-2025 | Libtayo, Dupixent |
| Epsfl, LLC | $350.17 | 2023 | |
| Novartis Pharmaceuticals Corporation | $314.08 | 2021-2025 | |
| Genzyme Corporation | $290.91 | 2019-2025 | |
| Smith+Nephew, INC. | $239.54 | 2022-2024 | Grafix, Oasis, Pico 14 |
| Amgen INC. | $191.71 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $166.59 | 2019-2025 | Nemluvio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $152.60 | 2024-2025 | Ycanth |
| Kerecis Limited | $134.45 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| E.R. Squibb & Sons, L.L.C. | $130.88 | 2024 | Sotyktu |
| Pfizer INC. | $129.39 | 2019-2024 | |
| Convatec INC. | $88.21 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.55 | 2020-2024 | Siliq |
| Ucb, INC. | $74.59 | 2021-2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Mayne Pharma Commercial LLC | $65.05 | 2019-2022 | |
| Dermavant Sciences, INC. | $60.97 | 2023-2024 | Vtama |
| Almirall LLC | $45.18 | 2022-2024 | Seysara |
| Kyowa Kirin, INC. | $29.71 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $27.75 | 2020 | |
| Organon LLC | $26.15 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $21.45 | 2023 | Shingrix, Arexvy |
| Genentech USA, INC. | $19.05 | 2021 | |
| Bioventus LLC | $17.08 | 2022 | |
| Reprise Biomedical, INC. | $15.73 | 2024 | Miro3d |
| Tempus Ai, INC | $13.21 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dorton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.